Explain the type 2 dm diagnosis and treatment step by step with drugs dose and frequency
Reading File
Finding Sources
Finding Sources
Searching PubMed
"type 2 diabetes" AND "management" AND "treatment"
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information. Let me compile the full, structured answer from all the textbook sources gathered.
Type 2 Diabetes Mellitus (T2DM): Diagnosis & Treatment — Step by Step
PART 1: UNDERSTANDING T2DM
T2DM accounts for ~90% of all diabetes cases. It is characterized by two core defects:
- Insulin resistance — skeletal muscle, liver, and adipose tissue fail to respond normally to insulin
- Progressive β-cell failure — insulin secretion becomes inadequate over time
Onset is insidious; many patients have irreversible complications (retinopathy, nephropathy, neuropathy) at the time of diagnosis.
Tietz Textbook of Laboratory Medicine, 7th Edition — "Many patients have irreversible complications at the time of diagnosis."
PART 2: SCREENING
Screen the following high-risk groups (ADA criteria):
| Risk Factor | Threshold to Screen |
|---|---|
| Age | ≥35 years, or any adult with overweight/obesity |
| BMI | ≥25 kg/m² (≥23 in Asian Americans) + ≥1 risk factor |
| Pre-diabetes (IFG/IGT) | Annual re-screening |
| Hypertension (≥140/90 mmHg) | Screen |
| First-degree relative with T2DM | Screen |
| History of gestational diabetes | Screen |
| Dyslipidemia (HDL <35 or TG >250 mg/dL) | Screen |
| Polycystic ovarian syndrome | Screen |
| Sedentary lifestyle, ethnicity (Hispanic, African American, Asian, Pacific Islander, Native American) | Screen |
Screening tests: FPG, HbA1c, or 2-h OGTT.
PART 3: DIAGNOSTIC CRITERIA
Any one of the following confirms diabetes (repeat testing required if asymptomatic):
| Test | Pre-Diabetes | Diabetes |
|---|---|---|
| Fasting Plasma Glucose (FPG) | 100–125 mg/dL (IFG) | ≥126 mg/dL |
| 2-h OGTT (75 g glucose) | 140–199 mg/dL (IGT) | ≥200 mg/dL |
| HbA1c | 5.7–6.4% | ≥6.5% |
| Random Plasma Glucose | — | ≥200 mg/dL + classic symptoms |
Rules:
- In the absence of classic hyperglycemia symptoms (polyuria, polydipsia, unexplained weight loss), two abnormal results are required (same or separate samples)
- In the presence of classic symptoms, a single random glucose ≥200 mg/dL is sufficient — no repeat needed
- FPG = no caloric intake for ≥8 hours
- OGTT uses 75 g anhydrous glucose in water; not recommended for routine clinical use
Goodman & Gilman's Pharmacological Basis of Therapeutics — Table 51-1; Tietz Textbook of Laboratory Medicine, 7th Ed
PART 4: TREATMENT — STEP-BY-STEP
Step 1: Set Individual Glycemic Targets
| Target | General Goal | Notes |
|---|---|---|
| HbA1c | <7.0% | <6.5% if safe (younger, no CVD risk, short duration); <8.0% in elderly/frail |
| Fasting glucose | 80–130 mg/dL | |
| 2-h post-meal glucose | <180 mg/dL | |
| BP | <130/80 mmHg | |
| LDL | <70–100 mg/dL | Statin therapy indicated |
ACCORD trial showed that targeting HbA1c <6.0% increased cardiovascular mortality by 22% — targets must be individualized.
Step 2: Lifestyle Modification (All Patients — First-Line)
Non-pharmacologic therapy is the foundation and should be initiated immediately at diagnosis and continued lifelong:
- Dietary changes: Reduced caloric intake, limiting refined carbohydrates and saturated fats; Mediterranean-style or low-carbohydrate diets
- Physical activity: 150 min/week of moderate-intensity aerobic exercise; resistance training 2–3×/week
- Weight loss: Even 5–10% reduction from baseline body weight significantly improves glycemia, BP, and lipids
- Smoking cessation, alcohol moderation
- SMBG (Self-monitoring of blood glucose): Especially important for patients on insulin
Step 3: First-Line Pharmacotherapy — Metformin
Start metformin at diagnosis (unless contraindicated) alongside lifestyle intervention.
| Drug | Dose | Frequency | Notes |
|---|---|---|---|
| Metformin IR (Glucophage) | Start 500 mg; titrate over weeks; target 1000–2000 mg/day; max 2550 mg/day | Twice daily with meals | Titrate slowly to reduce GI side effects |
| Metformin XR (extended release) | Start 500 mg/day; titrate to 2000 mg/day | Once daily with evening meal | Less GI side effects; useful if IR not tolerated |
Why metformin first?
- Lowers hepatic glucose production (inhibits Complex I of mitochondria → ↑AMP/ATP → activates AMPK → suppresses gluconeogenesis)
- Does not cause hypoglycemia; no weight gain
- Superior or equivalent efficacy vs. other oral agents
- Reduces microvascular complications (UKPDS)
- Cheap, well-tolerated
Contraindications: eGFR <30 mL/min/1.73m² (hold if eGFR <45 before contrast or surgery), hepatic failure, active alcohol abuse, lactic acidosis history
Monitor: Serum creatinine/eGFR, vitamin B12 levels (reduced by 20–30% long-term)
Goodman & Gilman's — "Metformin is generally accepted as the first-line treatment of type 2 diabetes and is the most commonly used oral agent"
Step 4: Add Second Agent (if HbA1c not at target in 3 months)
Choose based on patient comorbidities, weight, cost, and cardiovascular/renal risk:
A. Sulfonylureas (SUs) — Insulin Secretagogues
Bind SUR1 on β-cells → close K_ATP channels → depolarize → Ca²⁺ influx → insulin release.
| Drug | Starting Dose | Usual Dose | Max Dose | Frequency |
|---|---|---|---|---|
| Glipizide (Glucotrol) | 5 mg | 10–20 mg/day | 40 mg/day | Once or twice daily, before meals |
| Glipizide XL | 5 mg | 5–10 mg/day | 20 mg/day | Once daily |
| Glyburide (Micronase/DiaBeta) | 2.5 mg | 5–10 mg/day | 20 mg/day | Once daily (morning) |
| Glimepiride (Amaryl) | 1–2 mg | 1–4 mg/day | 8 mg/day | Once daily with breakfast |
| Gliclazide | 40 mg | 40–160 mg/day | 320 mg/day | Once or twice daily |
Caution: Hypoglycemia risk (especially glyburide in elderly and renal impairment); weight gain (~2 kg).
B. GLP-1 Receptor Agonists — Preferred with CVD or Obesity
Mimic incretin hormone GLP-1: stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, reduce appetite/weight.
| Drug | Starting Dose | Maintenance Dose | Route & Frequency |
|---|---|---|---|
| Semaglutide (Ozempic) | 0.25 mg/week × 4 wks | 0.5–1 mg/week (max 2 mg/week) | SC injection, once weekly |
| Semaglutide oral (Rybelsus) | 3 mg/day × 30 days | 7 mg/day → max 14 mg/day | Oral, once daily (fasting) |
| Liraglutide (Victoza) | 0.6 mg/day × 1 week | 1.2–1.8 mg/day | SC injection, once daily |
| Dulaglutide (Trulicity) | 0.75 mg/week | 0.75–1.5 mg/week (max 4.5 mg/week) | SC injection, once weekly |
| Exenatide (Byetta) | 5 mcg twice daily × 1 month | 10 mcg twice daily | SC injection, 60 min before meals |
| Exenatide ER (Bydureon) | 2 mg/week | 2 mg/week | SC injection, once weekly |
Preferred in: Established ASCVD (liraglutide, semaglutide have cardiovascular benefit), obesity (significant weight loss 3–7 kg), HF.
Side effects: Nausea, vomiting, diarrhea (usually transient); small risk of pancreatitis; avoid in personal/family history of MTC.
Side effects: Nausea, vomiting, diarrhea (usually transient); small risk of pancreatitis; avoid in personal/family history of MTC.
C. SGLT-2 Inhibitors (Gliflozins) — Preferred with Heart Failure or CKD
Block SGLT-2 in proximal tubule → glycosuria (urinary glucose excretion ~60–80 g/day) → lower blood glucose, BP, and weight.
| Drug | Dose | Frequency | Notes |
|---|---|---|---|
| Empagliflozin (Jardiance) | 10 mg (may increase to 25 mg) | Once daily | CV & renal benefit (EMPA-REG OUTCOME trial) |
| Canagliflozin (Invokana) | 100 mg; may increase to 300 mg | Once daily before first meal | CV & renal benefit |
| Dapagliflozin (Farxiga) | 10 mg | Once daily | HF benefit (DAPA-HF) |
| Ertugliflozin (Steglatro) | 5 mg; may increase to 15 mg | Once daily |
Preferred in: Heart failure (especially HFrEF), CKD (eGFR ≥30), established ASCVD with need for weight loss.
Side effects: Genital mycotic infections, UTI, volume depletion, euglycemic DKA (rare), lower limb amputation risk (canagliflozin).
Do NOT use: eGFR <30 mL/min/1.73m² (glucose-lowering effect lost; dapagliflozin/empagliflozin approved for HF/CKD benefits even at lower eGFR).
Side effects: Genital mycotic infections, UTI, volume depletion, euglycemic DKA (rare), lower limb amputation risk (canagliflozin).
Do NOT use: eGFR <30 mL/min/1.73m² (glucose-lowering effect lost; dapagliflozin/empagliflozin approved for HF/CKD benefits even at lower eGFR).
D. DPP-4 Inhibitors (Gliptins) — Weight Neutral, Safe
Inhibit DPP-4 enzyme → prolong endogenous GLP-1/GIP → glucose-dependent insulin release, reduce glucagon.
| Drug | Dose | Frequency |
|---|---|---|
| Sitagliptin (Januvia) | 100 mg/day (reduce to 50 mg if eGFR 30–45; 25 mg if eGFR <30) | Once daily |
| Saxagliptin (Onglyza) | 2.5–5 mg/day | Once daily |
| Linagliptin (Tradjenta) | 5 mg/day | Once daily (no renal dose adj. needed) |
| Alogliptin (Nesina) | 25 mg/day (dose reduce in CKD) | Once daily |
Side effects: Nasopharyngitis, possible pancreatitis (rare), joint pain; saxagliptin associated with increased HF hospitalization — avoid in HF.
E. Thiazolidinediones (TZDs) — Insulin Sensitizers
Activate PPARγ nuclear receptor → improve insulin sensitivity in muscle, fat, liver.
| Drug | Starting Dose | Usual Dose | Frequency |
|---|---|---|---|
| Pioglitazone (Actos) | 15–30 mg | 15–45 mg/day | Once daily |
| Rosiglitazone (Avandia) | 4 mg | 4–8 mg/day | Once or twice daily |
Side effects: Weight gain (2–4 kg), fluid retention/edema, heart failure risk (contraindicated in NYHA Class III/IV), increased fracture risk, bladder cancer risk (pioglitazone - controversial).
Benefit: Pioglitazone reduces MACE in patients with macrovascular disease (PROactive trial).
Benefit: Pioglitazone reduces MACE in patients with macrovascular disease (PROactive trial).
F. Alpha-Glucosidase Inhibitors — Postprandial Glucose
Inhibit intestinal α-glucosidase → delay carbohydrate digestion → reduce postprandial glucose spikes.
| Drug | Starting Dose | Max Dose | Frequency |
|---|---|---|---|
| Acarbose (Precose) | 25 mg | 300 mg/day | Three times daily with first bite of meals |
| Miglitol (Glyset) | 25 mg | 300 mg/day | Three times daily with meals |
Side effects: Flatulence, diarrhea, abdominal cramps (very common — limits use). No hypoglycemia if used alone.
G. Meglitinides (Non-SU Secretagogues)
Bind SUR1 (different site than SUs) → rapid, short-duration insulin release. Taken before meals only.
| Drug | Starting Dose | Max Dose | Frequency |
|---|---|---|---|
| Repaglinide (Prandin) | 0.5 mg (if HbA1c <8%) or 1–2 mg | 16 mg/day | 2–4× daily, 15–30 min before each meal |
| Nateglinide (Starlix) | 60–120 mg | 360 mg/day | Three times daily before meals |
Useful in: Irregular meal patterns (skip dose if meal skipped). Hypoglycemia risk < SUs.
Step 5: Triple Therapy (if 2-drug combination fails after 3 months)
Add a third agent from a different class. Common effective combinations:
- Metformin + GLP-1 RA + SGLT-2 inhibitor (recommended with CVD + obesity + CKD)
- Metformin + SU + DPP-4 inhibitor
- Metformin + TZD + SU
Step 6: Insulin Therapy
Indicated when:
- HbA1c remains >10% (or blood glucose >300 mg/dL) at presentation — start insulin immediately
- Oral agents fail despite dual/triple therapy
- Symptomatic hyperglycemia (polyuria, weight loss, ketosis)
- Hospitalization, surgery, pregnancy
Insulin Types & Doses
| Insulin Type | Examples | Onset | Peak | Duration | Starting Dose |
|---|---|---|---|---|---|
| Rapid-acting | Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra) | 5–15 min | 30–90 min | 3–5 h | 4 units before meals; titrate |
| Short-acting | Regular insulin (Humulin R, Novolin R) | 30–60 min | 2–4 h | 5–8 h | Given 30 min before meals |
| Intermediate-acting | NPH (Humulin N, Novolin N) | 1–3 h | 4–10 h | 12–18 h | Twice daily |
| Long-acting basal | Glargine (Lantus, Basaglar) | 2–4 h | No peak | ~24 h | 10 units SC at bedtime (or 0.1–0.2 units/kg/day); titrate by 2 units every 3 days |
| Long-acting basal | Detemir (Levemir) | 1–2 h | Mild peak | 12–24 h | 10 units once or twice daily |
| Ultra-long-acting | Degludec (Tresiba) | 1 h | No peak | >42 h | Once daily, flexible timing |
Initiation of basal insulin in T2DM:
- Add basal insulin (glargine 10 units at bedtime) to existing oral agents
- Titrate by 2 units every 3 days until FBG 80–130 mg/dL
- If HbA1c still not at goal, add prandial (rapid-acting) insulin at largest meal (basal-bolus regimen)
Textbook of Family Medicine 9e & Katzung's Basic and Clinical Pharmacology, 16th Ed
Step 7: Monitoring & Follow-up
| Parameter | Target | Frequency |
|---|---|---|
| HbA1c | <7% (individualized) | Every 3 months until stable, then every 6 months |
| Fasting glucose (SMBG) | 80–130 mg/dL | Daily (especially on insulin) |
| Post-meal glucose | <180 mg/dL | 2 hours after meals |
| Blood pressure | <130/80 mmHg | Every visit |
| Lipids (LDL) | <70–100 mg/dL | Annually |
| Urine albumin-to-creatinine ratio | <30 mg/g | Annually |
| eGFR/serum creatinine | Monitor | Annually |
| Foot exam | Inspect for neuropathy, PVD | Every visit |
| Eye exam (dilated) | — | Annually (from diagnosis in T2DM) |
| Vitamin B12 | (metformin users) | Periodically |
SUMMARY: Treatment Algorithm
DIAGNOSIS OF T2DM
↓
Step 1: Lifestyle modification (diet + exercise + weight loss) — ALL patients
↓
Step 2: Add METFORMIN (unless contraindicated)
500 mg BD, titrate to 1000–2000 mg/day
↓ (HbA1c still >7% after 3 months)
Step 3: Add second agent based on comorbidities:
• ASCVD/CVD risk → GLP-1 RA (liraglutide/semaglutide) or SGLT-2i (empagliflozin)
• Heart failure → SGLT-2i (dapagliflozin/empagliflozin)
• CKD → SGLT-2i (empagliflozin/canagliflozin)
• Weight loss need → GLP-1 RA > SGLT-2i
• Cost concern → SU (glipizide/glimepiride) or TZD (pioglitazone)
• Hypoglycemia risk (elderly) → DPP-4i or GLP-1 RA or SGLT-2i
↓ (still not at goal)
Step 4: Triple therapy (add third class)
↓ (still failing)
Step 5: Insulin — start basal insulin (glargine 10 units HS), titrate
→ Add prandial insulin if needed (basal-bolus)
Sources:
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (Table 51-1, Chapters on insulin/oral agents)
- Katzung's Basic and Clinical Pharmacology, 16th Edition (Chapter on pancreatic hormones and antidiabetic drugs)
- Tietz Textbook of Laboratory Medicine, 7th Edition (Diabetes diagnosis criteria)
- Textbook of Family Medicine, 9th Edition (Clinical management and individualized targets)
This is a shared conversation. Sign in to Orris to start your own chat.